Full-Time

Senior Clinical Trials Manager

Posted on 6/25/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical company developing innovative medicines

Compensation Overview

$143.2k - $185.3k/yr

+ Bonus + Stock-based long-term incentives

Senior

Company Historically Provides H1B Sponsorship

Remote in USA + 1 more

More locations: Parsippany-Troy Hills, NJ, USA

Remote

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • PhD/PharmD and 0+ years of relevant experience; OR
  • MA/MS/MBA and 4+ years of relevant experience; OR
  • BA/BS and 6+ years of relevant experience
  • Prior clinical trials/operations experience in company sponsored clinical trials
Responsibilities
  • Responsible for identifying cross-study synergies to leverage efficiencies and optimize performance across study teams (systems and technology, study design, decentralization, team/stakeholder communication, etc)
  • Partner with oncology leadership and cross-functional teams to define, build, lead, and drive strategic processes and portfolio analytics development.
  • Leverage strategic and analytical expertise to implement new portfolio management analysis approaches, methods, tools, and capabilities.
  • Reporting on study status (enrollment, SSU, etc) to optimize and drive data-driven decision making.
  • Leads and participates in moderately complex assignments that enable multiple functions and teams to achieve their clinical study objectives within targeted timelines and allocated resource levels.
  • Collaborates with other functions on how to best achieve their clinical goals and objectives.
  • Potential to serve as Oncology Subject Matter Expert on cross-functional initiatives to further optimize organizational reporting capabilities and systems.
  • Drives aspects of CRO oversight to ensure the overall program(s) is completed compliantly, on-time, within-budget and to the quality expected.
  • Consistently models our Leadership Commitments and Values for others to follow.
  • Has the managerial courage to speak-up when needed, and in a manner that moves the business and team forward.
  • Gives constructive, fair, balanced, concise and actionable feedback.
  • Takes accountability to ensure change is understood and implemented well.
  • Effectively influences without authority.
  • Ensure study delivery is on time, as per scope and compliance, and within the allocated budget.
  • Demonstrates ability to think short- and long-term in devising appropriate project strategies and approaches to completing project deliverables.
  • Coaches and guides less experienced team members in solving problems.
Desired Qualifications
  • Proficient in Excel and use of data to drive data-driven strategies and decision making, and to create data analytics/visualizations.
  • Has advanced knowledge of study management best practices and tools and has shown ability to apply these to improve project efficiencies and effectiveness.
  • Has significant industry (ICH/GCP and FDA/EMA regulations) knowledge, including knowledge of drug development, and is able to flex own knowledge to work on studies of varying scope and complexity.
  • Working knowledge and experience with Word, PowerPoint and Excel
  • Prior oncology clinical trials experience

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead differentiates itself from competitors through its strong commitment to R&D, maintaining a diverse pipeline of potential treatments, and forming strategic partnerships to enhance its offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's oncology navigation grant program enhances its reputation in cancer care.
  • The $11 billion investment is expected to create significant economic value and jobs.
  • Partnerships in innovative cancer treatments position Gilead at the forefront of oncology.

What critics are saying

  • Layoffs and halted expansion plans indicate potential operational challenges in biologics.
  • The $202 million settlement may impact Gilead's financial standing and reputation.
  • Intensifying competition from companies like Amgen pressures Gilead's market performance.

What makes Gilead Sciences unique

  • Gilead's partnership with Kymera focuses on novel cancer treatments using molecular glue degraders.
  • The company invests heavily in R&D, with a $11 billion U.S. investment plan.
  • Gilead's collaborations aim to improve patient outcomes and healthcare access globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

Plant Services
Jul 4th, 2025
Factory fallout: Manufacturing plant closures and layoffs from Intel, Hasbro, Johnsonville, and more

According to Fierce Biotech, Gilead Sciences, a pharmaceutical company, is laying off 36 employees as part of a strategic shift that ended plans to expand its biologics facility in Oceanside, California.

Pipeline Review
Jun 26th, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences and Kymera Therapeutics enter into exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders.

24-7 Press Release
Jun 26th, 2025
Gilead Sciences, Inc. proudly Supports Unite for HER's Metastatic Breast Cancer Sustainer Program

PHILADELPHIA, PA, June 26, 2025 /24-7PressRelease/ - Unite for HER (UFH) and Gilead Sciences have partnered to provide a new integrative care program free to Black, Hispanic, and underserved metastatic breast cancer patients in the United States.

BioPharma Dive
Jun 25th, 2025
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

Gilead and Kymera will develop a molecular glue degrader for breast cancer and other solid tumors.

PR Newswire
Jun 1st, 2025
The Academy Of Oncology Nurse Patient Navigators And Gilead Sciences Partner To Launch Oncology Navigation Grant Program

GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation and enhancing patient outcomes within the healthcare setting. This initiative is designed to support the creation, enhancement, and expansion of innovative tools that optimize efficiency and elevate the critical role of oncology navigators.Following the AONN+ call for grant submissions in April, healthcare leaders across the country responded with creative applications, software solution ideas and healthcare system improvements. AONN+ looks to announce the recipients of the award, valued up to $500,000, in June with project work to begin in the July time frame. The AONN+ grant application process and implementation support for awardees also included help from Amplity, AONN+'s association management partner and strategic collaborator."Through this funding mechanism, AONN+ and Gilead are committed to addressing persistent challenges in cancer care by empowering navigators to play a pivotal role in improving patient access to navigation services, removing barriers to cancer care, and supporting treatment adherence," says Candice Roth, MSN, RN, CENP, Executive Director, AONN+. "Navigator utilization continues to present significant opportunities for optimizing patient outcomes, and this program seeks to provide impactful solutions that directly tie proposed tools to measurable improvements in patient care.""As part of Gilead's Community Cancer Collective, we are proud to partner with AONN+ on this exciting initiative in support of the oncology community," said Darren Tayama, M.D., Vice President, US Medical Affairs, Oncology. "Together, AONN+ and Gilead are advancing the future of cancer care through innovative solutions in oncology navigation."About the Academy of Oncology Nurse & Patient Navigators , Inc

INACTIVE